Roivant announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. Mayukh Sukhatme, M.D., has served as Roivant’s President and Chief Investment Officer since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ROIV:
- Is ROIV a Buy, Before Earnings?
- JPMorgan biotech analyst to hold an analyst/industry conference call
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant